Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia

肺泡T细胞反应的独特演变与未接种疫苗的SARS-CoV-2肺炎患者的临床结局相关

阅读:9
作者:Nikolay S Markov ,Ziyou Ren # ,Karolina J Senkow # ,Rogan A Grant ,Catherine A Gao ,Elizabeth S Malsin ,Lango Sichizya ,Hermon Kihshen ,Kathryn A Helmin ,Milica Jovisic ,Jason M Arnold ,Xóchitl G Pérez-Leonor ,Hiam Abdala-Valencia ,Suchitra Swaminathan ,Julu Nwaezeapu ,Mengjia Kang ,Luke Rasmussen ,Egon A Ozer ,Ramon Lorenzo-Redondo ,Judd F Hultquist ,Lacy M Simons ,Estefany Rios-Guzman ,Alexander V Misharin ,Richard G Wunderink ,G R Scott Budinger ,Benjamin D Singer # ,Luisa Morales-Nebreda #

Abstract

The evolution of T cell molecular signatures in the distal lung of patients with severe pneumonia is understudied. Here, we analyzed T cell subsets in longitudinal bronchoalveolar lavage fluid samples from 273 patients with severe pneumonia, including unvaccinated patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with respiratory failure not linked to pneumonia. In patients with SARS-CoV-2 pneumonia, activation of interferon signaling pathways, low activation of the NF-κB pathway and preferential targeting of spike and nucleocapsid proteins early after intubation were associated with favorable outcomes, whereas loss of interferon signaling, activation of NF-κB-driven programs and specificity for the ORF1ab complex late in disease were associated with mortality. These results suggest that in patients with severe SARS-CoV-2 pneumonia, alveolar T cell interferon responses targeting structural SARS-CoV-2 proteins characterize individuals who recover, whereas responses against nonstructural proteins and activation of NF-κB are associated with poor outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。